Item 5.02 Results of Operations and Financial Condition.

On January 9, 2023, Apellis Pharmaceuticals, Inc. (the "Company") posted on its website a corporate presentation, which it plans to present at the 41st Annual J.P. Morgan Health Care Conference on January 9, 2023. In the corporate presentation, the Company disclosed that based on preliminary financial information it expects to report that it recorded approximately $65 million in net product revenue from sales of EMPAVELI in the United States for the year ended December 31, 2022. The related excerpt from the presentation is attached as Exhibit 99.1 hereto.

The Company's net product revenue figure is preliminary and unaudited, represents management's estimate as of the date of this report and is subject to completion of the Company's financial closing procedures. The Company's independent registered public accounting firm has not conducted an audit or review of, and does not express an opinion or any other form of assurance with respect to, the Company's net product revenue from sales of EMPAVELI.

The information in this Item 2.02, including Exhibit 99.1 hereto, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.





Exhibit No.       Description

99.1                Excerpt from corporate presentation dated January 2023

104               Cover Page Interactive Data File (embedded within the Inline XBRL
                  document)

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses